Telitacicept Add-On Boosts Renal Response in Proliferative Lupus Nephritis

This real-world comparative analysis suggests dual B-cell activating factor/proliferation-inducing ligand (BAFF/APRIL) blockade with telitacicept added to standard care raises complete renal response rates and accelerates glucocorticoid tapering in proliferative lupus nephritis, informing induction regimen selection.

telitaciceptbelimumabBAFF/APRIL inhibitorTACI-Fc fusion proteinproliferative lupus nephritislupus nephritissystemic lupus erythematosusglucocorticoid sparingretrospective cohortIPTWinduction therapyrheumatologynephrology Rheumatology / Immunology

Background Information

Telitacicept enhances renal response in lupus nephritis.

Telitacicept combined with standard care improves renal outcomes for patients with proliferative lupus nephritis, potentially enhancing current treatment protocols. At week 24, patients on telitacicept had higher complete renal response (67.9% vs 39.3%, p=0.004) and partial renal response rates (83.9% vs 67.9%, p=0.023) compared to controls. This study indicates that telitacicept may offer a more effective induction therapy for proliferative lupus nephritis, although these findings require validation in broader clinical trials. Telitacicept significantly boosts renal response rates in proliferative lupus nephritis, offering potential for reduced glucocorticoid use.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Tian T, Zhang A, Liu X, Wu P, Li N, Zeng L, Liu J, Qin L, Zeng J

Citation: Tian T, Zhang A, Liu X, et al. Efficacy and safety of telitacicept combined with standard of care in patients with proliferative lupus nephritis: a real-world retrospective study. Lupus science & medicine. 2026;13(2). doi:10.1136/lupus-2026-002191

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →